Donepezil treatment of Alzheimer's disease patients in California clinical practice: One year follow-up

Tinklenberg, Jared R.; Newkirk, Lori A.; Thompson, Jordan M.; Ross, Lainie S.; Davies, Helen D.; Shakoori, Roxanne; Taylor, Joy L.; O’Hara, Ruth; Kraemer, Helena C.; Yesavage, Jerome A.

doi:10.1016/s0924-977x(01)80446-6

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data provided the longest‐term efficacy data for any ChE‐I to date. Even though only 83 patients remained under study conditions at 5 years, these data can be considered informative, because most patients tend to discontinue ChE‐I treatment over time (14,15). As rivastigmine became licensed in more countries, many patients withdrew from the study, because they were able to take rivastigmine without scheduled visits and other protocol requirements.…”

Section: Long‐term Studies Of Che‐ismentioning

confidence: 99%

See 1 more Smart Citation

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Bullock

Dengiz

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

The cholinesterase inhibitors (ChE-Is)--rivastigmine, donepezil and galantamine--demonstrated efficacy in large, 6-month, double-blind, placebo-controlled trials, and are widely used for the symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD). Over the past few years, data have emerged, suggesting that these agents may have long-term benefits. These data have been summarized in this study, followed by an interpretation of clinical relevance. Data were identified by searches of Medline((R)) and references from relevant English-language articles. The search words 'Alzheimer', 'donepezil', 'rivastigmine', 'galantamine' and 'long term' were used. In addition, recent data presented at international congresses and/or provided by colleagues in this field of research were included in order to ensure maximum topicality. Data are available showing cognitive performance in patients remaining on rivastigmine for up to 5 years (n = 83), donepezil for up to 4.9 years (n = 18) and galantamine for up to 4 years (n = 185). Most of these data come from open-label studies and need to be interpreted with caution. The data appear to suggest that patients, caregivers and physicians will still see some decline on ChE-Is after a period of stabilization, but this may be slower and later than expected if the patients were left untreated. This applies across all domains of AD - not simply cognition - and function can be relatively preserved, even if cognitive scores are falling. Despite the limitations of current data, the information reviewed in this study may help practising doctors assess the long-term value of ChE-Is in this consistently progressive disease.

show abstract

Section: Long‐term Studies Of Che‐ismentioning

confidence: 99%

“…Current average duration of treatment is relatively short term (14,15). Treatment withdrawal may reflect unrealistic efficacy expectations, lack of efficacy or poor tolerability, as well as loss of efficacy or adverse effects emerging during the maintenance phase.…”

Section: Expert Opinionmentioning

confidence: 99%

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Bullock

Dengiz

2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…when patients no longer respond to treatment. At least 25% of patients withdraw from treatment with an ChE inhibitor within the first year 14 . In other therapeutic areas, it is common medical practice to switch non responders to alternative treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Research design and methods: A prospective, multicentre, 3-month Research design and methods: A prospective, multicentre, 3-month Research design and methods: observational trial in patients with mild to moderately severe AD (adjusted Mini Mental State Examination [MMSE] score [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] deteriorating (at least 2 adjusted MMSE points in last 6 months) on selective AChE inhibitor treatment. Adjusted MMSE, activities of daily living (ADL) and instrumental activities of daily living (IADL), the Zarit caregiver burden and global function (short Clinical Global Impression of Change, CGIC) scores were noted before the switch and 3 months after the switch.…”

mentioning

confidence: 99%

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

Bartorelli

Giraldi

et al. 2005

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Donepezil treatment of Alzheimer's disease patients in California clinical practice: One year follow-up

Cited by 2 publications

References 0 publications

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

Contact Info

Product

Resources

About